Creating faster, more accurate
solutions in early cancer screening

We provide the most comprehensive, non-invasive,
highly-sensitive early stage cancer screening process
on the market with the CA-62 test.

get updates

scientific publications

Testing Overview

RECAF review book chapter Moro.pdf

Publications

  1. J. Tcherkassova, S. Tsurkan, A. Prostyakova, E. Klinski, R. Moro, A. Boroda, M. Sekacheva, and David Berz. A NOVEL 3 BIOMARKERS SIGNATURE (CA-62, CEA, CYFRA 21-1) FOR EARLY-STAGE NSC LUNG CANCER DETECTION. Journal of Clinical Oncology Vol 41 issue 16, Abstract ASCO 2023 annual meeting, A novel three-biomarker signature.
  2. J. Cherkassova, A. Prostyakova, S. Tsurkan, V. Ragoulin, A. Boroda, and M. Sekacheva. Diagnostic Efficacy of the new prospective biomarker's combination CA 15-3 and CA-62 for early-stage breast cancer detection: Results of the blind prospective-retrospective clinical study. Cancer Biomarkers, vol. 35, pp. 57-69, June 2022.
  3. A pilot clinical trial to monitor response to chemotherapy using the CA-62 marker of epithelial carcinomas. Khakimova Gulnoz G., Cherkasova Zhanneta R., Tsurkan Sergey A., Fedchikov Gleb A., Suganov Nikolay V., Gorbunova Vera A. Siberian Journal of Oncology, 2019, V.18, N.5, p. 18-28.
  4. Tcherkassova J.R., Tsurkan S.A., Smirnova G.B., Borisova J.Y., R. Moro, and Treshalina H.M. Binding characterization of the targeting drug AIMPILA to AFP receptors in human tumor xenografts. Tumor Biology, 2017, Oct, 9, p. 1-10.
  5. Moro R. Combination of RECAF with other markers improves cancer diagnosis. Abstracts of ISOBM 2017 Congress for Tumor Marker Publication, Tumor Biology, December 2017, p. 16
  6. Moro R. The alpha-fetoprotein receptor (RECAF): characterization and potential use for cancer diagnosis and therapy. Alpha-Fetoprotein: Functions and Clinical Applications Chapters Books, Nova Science Publishers, 2016, p.241-276
  7. Tsurkan S., Tcherkassova J., Gorbunova V., Treshalina H. New drug AIMPILAa targeted to AFP receptor: oral anticancer therapy and biodistribution in vivo. Journal of Clinical Oncology, 2018, Т. 15_suppl. С. e24232.
  8. Treshalina H.M., Smirnova G.B., Tsurkan S.A., Tcherkassova J.R., Lesnaya N.A. The role of alpha-fetoprotein receptor in the delivery of targeted preparations in oncology. Russian Journal of Oncology, 2017, Vol. 22, N 1, p.4-14 ISSN 2412-9119.
  9. Cherkasova Zh.R., Tsurkan S.A., Smirnova G.B., Borisova Yu.A., Treshalina E.M. Expression of AFP-receptors in human tumor homogenates SW620, T47D and in cell culture HepG2 from the collection of the Blokhin Russian Cancer Research Centre. Russian Journal of Biotherapy, 2016, V. 1, N.15:p.116-7.
  10. Cherkasova Zh.R., Tsurkan S.A., Smirnova G.B., Borisova Yu.A., Treshalina E.M. Binding specificity of Aimpila with AFP receptors on the surface of human tumor T47D from the collection of the Blokhin Russian Cancer Research Centre. Russian Journal of Biotherapy, 2016, V.1, N.15, p.117.
  11. Ricardo Moro, Janneta Gulyaeva-Tcherkassova, Petra Stieber. Increased AFP-Receptor (RECAF) values in the serum of patients with early stages of breast cancer. Journal of Current Oncology, 2012, Vol. 19, N.1, p. 1-8.
  12. Janneta Tcherkassova, Carolina Abramovich, Rafael Moro, Chen Chen, Ralph Smit, Angela Gerber, Ricardo Moro. Combination of CA125 and RECAF biomarkers for early detection of ovarian cancer. Tumor Biology, 2011, Vol. 32, No.4, p.831-838.
  13. Tcherkassova J, Moro R. RECAF as a replacement for free PSA in prostate cancer detection. Tumor Biology 2011, V 32, p.71
  14. Irene NG, Janneta Tcherkassova, Nina Lyubimova, Ricardo Moro. A new RECAF ELISA and Its Correlation with the Chemiluminescence RECAF Assay. Tumor  Biology, 2008, V. 29 (Suppl. 1), p. 41.
  15. Barry Dowell, Stephen Frost, Janneta Tcherkassova, Angela Gerber, Rafael Moro, and Ricardo Moro. Chemiluminescent assay (CIA) for the receptor of ALPHA FETOPROTEIN (RECAF) to separate cancer from normal sera. Tumor Biology, 2007, V. 28 (Suppl. 1), p.92
  16. Janneta Tcherkassova, Ralph Schmid, Xiaolong Hu, Nina Lyubimova, Ricardo Moro. Point-of-care serum test for cancer detection based on the RECAF cancer marker. Tumor Biology, 2007, V. 28 (Suppl. 1), p.101
  17. Ricardo Moro, Angela Gerber and Janneta Tcherkassova. High Discrimination between Prostate Cancer, Benign and Normal Serum Samples Using RECAF. Tumor Biology, 2006, V. 27 (Suppl. 2), p.57
  18. R. Moro, J. Tcherkassova, A. Gerber. High discrimination between Prostate cancer, Benign and Normal serum samples using the cancer marker RECAF. Journal of Clinical Chemistry, 2005, V. 52, Suppl. 6, p. 26
  19. https://secureservercdn.net/72.167.241.46/743.2ba.myftpupload.com/wp-content/uploads/2020/12/Ricardo2016NovaScience-122648.pdf
  20. Moro R., Tcherkassova J., Smith R., Gerber A., Moro R. RECAF marker reduce unnecessary prostate biopsies by 70% while detecting 80% of prostate cancer at stages I & II and 92% at all stages. 2022, in press.
  21. Moro R., Gulyaeva–Tcherkassova J., Stieber P. Increased alpha-fetoprotein receptor in the serum of patients with early-stage breast cancer. Current Oncology,  2012 Vol. 19 (1), p. 1-8
  22. Tcherkassova J, Abramovich C, Moro R, Chen Chen, Schmit R, Gerber A, Moro R. Combination of CA125 and RECAF biomarkers for early detection of ovarian cancer Tumor Biology, 2011, Vol. 32, No.4, p. 831-838
  23. Moro R, Tcherkassova J, and Moro R.J. Combination of CEA and the receptor to AFP (RECAF) for colorectal cancer screening. IOBM meeting, 2009, Amsterdam, Holland.
  24. B.Dowell,S. Frost (Abbott laboratories), J.Cherkassova, G.Gerber, R.Moro and R.Moro . Development of a Chemiluminescent Assay for the Receptor of Alha Fetoprotein to Separate Cancer from Normal Sera. XXXVth Congress of the International Society of Oncodevelopment Biology and Medicine, 2007, Prague, Czech Republic.
  25. R. Moro md,* J. Gulyaeva–Tcherkassova, and P. Stieber. Increased alpha-fetoprotein receptor in the serum of patients with early-stage breast cancer. Current Oncology, Volume 19, Number 1, February 2012, p. 1-8.
  26. A. Nicolini, A. Carpi, P. Ferrari, G. Rossi. Immunotherapy prolongs the serum CEA–TPA–CA15.3 lead time at the metastatic progression in endocrine-dependent  breast cancer patients: A retrospective longitudinal study. Cancer Letters 263, 2008, p.122–129
  27. R. Moro, J. Tcherkassova, E. Song, G. Shen, R. Moro, R. Schmid, X. Hu, A. Kummer, and Ch. Chen. A new broad-spectrum cancer marker. A novel receptor protein shows promise for detecting a wide range of malignancies. IVD Technology Magazine, June 2005.
  28. Bo Lin, Qiujiao Wang, Kun Liu, Xu Dong, Mingyue Zhu, and Mengsen Li. Alpha-Fetoprotein Binding Mucin and Scavenger Receptors: An Available Bio-Target for Treating Cancer. Front. Oncol., 25 February 2021, https://doi.org/10.3389/fonc.2021.625936 (https://doi.org/10.3389/fonc.2021.625936) 
  29. CA-62: A new biomarker for the detection of early-stage renal cell carcinoma. (https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.4526) 
  30. The Challenge of Early-stage Cancer Detection